Novartis Medical’s Post

At Novartis, our long-standing commitment to patients living with chronic myeloid leukemia (CML) spans more than two decades, marked by breakthroughs that have helped turn what was once a life-limiting condition into a chronic one for many. Yet, there's more ground to cover. Despite advancements, many patients still face hurdles such as lower response rates, treatment resistance, and intolerance, and have poor quality of life. That’s why we’re committed to continuing to pioneer targeted treatments for CML, and ensuring every patient has access to innovative medicines. Learn more here: https://lnkd.in/gadSYVJg

Acute Myeloid Leukemia (#AML) is the most common acute leukemia affecting adults, and the development of targeted therapies is helping to improve treatment options for patients across molecularly defined subsets. At Servier, we're continuing to drive advancements in AML research as part of our ongoing commitment to improving the lives of patients. Learn more about AML: https://lnkd.in/eFA3_aYi

Patients deserve strong, clinically relevant data to support the treatment decisions they make with their healthcare provider. At BeiGene, we are propelled by cutting edge science, including elevating head-to-head clinical studies and new statistical analyses of the BTK inhibitor landscape that can help to inform those decisions.    This is why I am pleased to have an article featured in Fierce Pharma where I highlight BeiGene’s latest efficacy analysis, which compares our BTK inhibitor with another in the relapsed / refractory chronic lymphocytic leukemia (#CLL) landscape. Learn more about how our MAIC analysis improves upon recently published research and why methodology matters when it comes to comparing treatments across data sets: https://bit.ly/3J0SKQw. #patientsfirst

In relapsed or refractory NPM1-mutant acute myeloid leukemia, FLT3-ITD co-mutations are common (49%), and prognosis is poor. In this population, only 14% of patients treated with a FLT3 inhibitor achieve a complete remission. KOMET-008 is a phase 1 trial that will examine ziftomenib, a menin inhibitor, in combination with the FLT3 inhibitor gilteritinib in patients with NPM1-m/FLT3 co-mutations. NPM1-m patients without a FLT3 co-mutation and KMT2A-r patients will receive ziftomenib in combination with FLAG-IDA or LDAC. OPENING SOON. Learn more: https://lnkd.in/g37mAZZq

Notable Labs announced the advancement of its volasertib Phase 2 program utilizing PPMP to enrich the study population for clinical responders. Notable is developing its lead drug asset volasertib with its proprietary PPMP for patients with relapsed/refractory acute myelogenous leukemia (r/r AML). “PPMP’s recently reported, 100% accurate prediction of fosciclopirox’s clinical trial outcome has allowed us to eliminate an entire 30-patient cohort from the planned volasertib program,” said Thomas A. Bock, MD, MBA, Chief Executive Officer of Notable Labs. “This further validates our PPMP-guided development strategy to target responding patients, improve patient outcomes and reduce the risk, time, and cost of drug development.”  More information at https://lnkd.in/e7UkBsBP.   #fosciclopirox #PPMP #drugdevelopment #hematology #hematologists  #bloodcancer #precisionmedicine #leukemia #AML #MDS #cancerresearch

NOW ONLINE New Review discusses resistance mechanisms based on cell interactions and secreted soluble factors in the #HematopoieticNiche and provides an overview of niche-related therapeutic targets for #AcuteMyeloidLeukemia therapy 🔓 OPEN ACCESS ➡ https://lnkd.in/dwpD-yzd The expansion of acute myeloid leukemia (AML) blasts not only suppresses normal hematopoiesis, but also alters the microenvironment. The interplay of different components of the bone marrow gives rise to altered metabolic states and activates signaling pathways which lead to resistance and impede effective therapy. Therefore, the underlying processes and mechanisms represent attractive therapeutic leverage points for overcoming therapy resistance in AML. Here, we briefly discuss resistance mechanisms based on cell interactions and secreted soluble factors in the hematopoietic niche and provide an overview of niche-related therapeutic targets currently undergoing preclinical and clinical investigation which may help improve the outcome in AML therapy.

The latest in ACP #Gastroenterology Monthly: http://ow.ly/EneC50HcMkX 🔸 IV iron appears safe, effective for bleeding-related iron-deficiency anemia in cirrhosis 🔸 GLP-1s associated with lower risk of hepatic decompensation than other diabetes drugs 🔸 Colectomy linked with greater risk of AKI, kidney failure in patients with IBD 🔸 Spotlight on colorectal cancer screening intervals

I'm excited to share another impactful study, titled "Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens", published in Haematologica Journal! This study from Universitätsklinikum Schleswig-Holstein explores a crucial aspect of acute myeloid leukemia treatment. 💡 Although immediate treatment initiation is standard for newly diagnosed AML, this study using TriNetX suggests that deferring therapy to assess comorbidities/risk factors does not negatively impact survival. Analysis of 855 patients (138 from SAL-registry and 717 from TriNetX) showed no significant survival difference between early and delayed treatment groups. Delaying venetoclax-based therapy can be a safe option with proper clinical monitoring. Read the full study here: https://lnkd.in/d6EfFNtr A big thank you to Dr. David Baden for his hard work and dedication! #LeukemiaResearch #Venetoclax #CancerResearch

KOMET-008 is actively recruiting for patients with relapsed/refractory NPM1-mutant or KMT2A-rearranged acute myeloid leukemia. KOMET-008 is a Phase 1 study to assess the safety and recommended Phase 2 dose of ziftomenib in combination with gilteritinib (for patients with a FLT3 co-mutation), FLAG-IDA, or LDAC. To find out more about this trial and the KOMET clinical trial program, visit https://lnkd.in/eUriz4NM